Aim: Interstitial lung disease (ILD) in infants represents a rare and heterogenous group of disorders, distinct from those occurring in adults. In recent years a new entity within this category is being recognized, namely filamin A (FLNA) mutation related lung disease. Our aims are to describe the clinical and radiological course of patients with this disease entity to aid clinicians in the prognostic counseling and management of similar patients they may encounter.
| INTRODUCTION
Interstitial lung disease (ILD) in infants represents a rare and heterogenous group of disorders, distinct from those occurring in adults. In 2007, the ChILD (Children's Interstitial Lung Disease) research co-operative proposed a new classification scheme for diffuse pulmonary lung diseases encompassing a variety of genetic and developmental etiologies. 1 The classification was based upon biopsy and imaging results from eleven centers contributing 187 cases of diffuse lung disease in infancy over a 5-year study period. This has been incorporated into the latest 2013 American Thoracic Society Clinical Practice Guideline: Classification, Evaluation, and Management of Childhood Interstitial Lung disease in Infancy and serves as a framework by which to build upon, with discovery and delineation of molecular and specific etiologies adding to this classification with time. 2, 3 In recent years a new disease entity is being increasingly recognized, namely filamin A (FLNA) mutation related lung disease.
Filamin A is an actin-binding protein expressed ubiquitously within the body with multiple roles both in cell signaling and maintenance of Abbreviations: ASD, atrial septal defect; BiPAP, bilevel positive airway pressure; ChILD, Children's Interstitial Lung Disease; CPAP, continuous positive airway pressure; CT, computed tomography; ECHO, echocardiography; ETT, endotracheal tube; FLNA, Filamin A; HFOV, high flow oxygen ventilation; ILD, interstitial lung diseases; PDA, patent ductus arteriosus; PFO, patent foramen ovale; PICU, paediatric intensive care unit; MDT, multidisciplinary team; NIV, non-invasive mechanical ventilation; VSD, ventricular septal defect.
Presentations: This work has previously been presented as an educational e-poster at the International Pediatric Radiology (IPR) Conference held in Chicago, USA in June 2016. It has not been published, nor is it being considered for publication elsewhere. however, pulmonary manifestations are only just being described with four published case reports to date [7] [8] [9] [10] and a further five patients altogether reported within two separate poster abstract publications. 11, 12 In the cases reported, radiographic features have mimicked those of congenital lobar emphysema with hyperlucent pulmonary parenchyma, multi-lobar hyperinflation and pulmonary vascular attenuation.
Pathology obtained from lung biopsy or resection have revealed a combination of alveolar simplification, emphysematous changes, and pulmonary arteriopathy suggesting that mutations of FLNA appear to result in alveolar growth abnormality and thus reflect another causal etiology within the referenced classifications. 1, 13 In nearly all cases treatment has involved either lobar resection or lung transplantation 6,7,10 with only one case reported where supportive therapy was successful. 8 Given the progressive nature of this disease and potentially fatal outcomes, we present our own case series of four patients with genetically confirmed FLNA mutation and associated pulmonary manifestations. This case series will focus on clinical and radiographical findings of this condition with the aim of raising awareness and improving identification of this rare entity.
| METHODS
A retrospective case note review was conducted of all patients treated at our institution (a specialist tertiary referral childrens' center) for genetically confirmed FLNA mutation related lung disease. Patients tested for FLNA mutation without lung disease were excluded from this analysis.
At our institution, all genetic testing for FLNA is performed on peripheral blood samples, at an off-site UKAS accredited genetic laboratory by use of bi-directional Sanger sequencing. Determination of pathogenicity of variants are carried out at the laboratory using bioinformatics software Alamut v 2.0 (Interactive Biosoftware, Rouen, France).
The clinical presentation, evolution, management, and radiological features were recorded and a medical literature review of Medline 
| RESULTS
Over the last 10 years at our institution, there have been four genetically confirmed cases of FLNA mutation related lung disease. An overview of the genetic abnormalities, key radiographical features, and clinical outcomes are provided in Table 1 . A detailed case review of each patient is outlined below.
| Case 1
A female infant with a normal antenatal course was delivered via elective Cesarean section at 36 + 5 weeks gestation due to breech presentation. The delivery was otherwise unremarkable and the patient was discharged home on her second day of life. Although initially thriving, her weight gain plateaued at 6-8 weeks of age.
At 3 months of age the patient was admitted to her local hospital with sudden onset difficulty in breathing. Oxygen saturations were low at 80% in air, improving to 100% with 2 L of oxygen via nasal cannula. A chest radiograph ( Haematoxylin and eosin stained histopathology images of (A) the initial wedge biopsy of lung including the pleura and (B) a representative post-mortem section of the patient's lung from case 1. The wedge biopsy reveals simplification of the alveolar architecture with dilatation of the distal airspaces. There is peribronchial fibrosis and focal haemorrhage. The post-mortem section demonstrates thickened alveolar septa and contain double capillary loops. This appearance was present throughout the lung and is the diagnostic feature of atypical congenital alveolar dysplasia. There is marked intra-alveolar oedema. Elsewhere within the lung there was fibrosis and airspace dilatation
Given the lack of clear diagnosis for the lung changes, molecular genetic testing was sought. There was no evidence for cystic fibrosis, pulmonary surfactant protein B (SFTPB), or C (SFTPC) ABCA3 gene deficiencies or any immunodeficiencies.
At the age of 5 months, she underwent PDA ligation and right lung wedge biopsy (Fig. 3A) . The biopsy results demonstrated poor alveolar development and immaturity with mild thickening of the small arteries.
A post-operative echocardiogram revealed reduction in pulmonary pressures with only a small residual atrial septal defect (ASD) remaining.
The patient was eventually weaned from ventilation and extubated at age 6 months onto bilevel positive airway pressure (BiPAP) support. She was then cycled to continuous positive airway pressure (CPAP) for increasing durations and discharged from the intensive care unit to the ward. Shortly after she developed pyrexia and loose stools rapidly escalating to respiratory distress and arrest.
She was re-intubated and ventilated and transferred to the PICU. After discussion with family and medical teams, the decision was made to form a tracheostomy at age 8 months.
Unfortunately the patient was unable to recover from the event, requiring continued oxygen and ventilator support, and died shortly after aged 9 months. A postmortem examination was interpreted as atypical congenital alveolar dysplasia. There were no areas of normal lung tissue, nor any large cysts or active infection (Fig. 3B ). Further genetic testing performed post-mortem revealed a mutation in the FLNA gene, felt to be contributory to the severe lung changes.
| Case 2
A term female infant with an unremarkable antenatal course was noted to have poor weight gain during the early months of her life. At the age of 7 months, her parents reported one episode of choking during a swimming outing in a chlorinated pool. There was no concern regarding near drowning or requirement for poolside resuscitation however the parents decided to take the infant to her local hospital for
review. An admission chest radiograph was performed and demon- Given the destructive lung changes, genetic analysis was sought and a mutation of the FLNA gene was identified. Due to the known association between FLNA mutation and neurological abnormalities, an MRI of the brain was performed demonstrating periventricular nodular heterotopia (PVNH), although the patient was not suffering from any neurological symptoms at this stage. FIGURE 6 Histopathology lung biopsy image from case 2 with elastic van Gieson staining. There is marked dilatation of the distal air spaces without thickening of the walls. The included muscular pulmonary arteries are thick walled in keeping with pulmonary arterial hypertension. There is also some artefactual alveolar haemorrhage After multiple unsuccessful attempts at extubation, the patient was transferred to a tertiary specialist children's hospital for further care. A chest CT at this stage, aged 2 months, revealed pan lobular emphysematous changes within both lungs with hyperinflation of the upper lobes and right middle lobe (Fig. 7) . At 3 months of age she was successfully extubated and placed on non-invasive mechanical ventilation (NIV) support. A bronchoscopy at this time demonstrated left lower lobe bronchomalacia and multiple bronchial stenoses. A transthoracic echocardiography revealed a structurally normal heart without any evidence of pulmonary hypertension.
After a prolonged course of NIV support and difficulty weaning from CPAP, the decision was made to site a tracheostomy at 6 months of age. The patient was slowly established on a portable ventilator via the tracheostomy with improvement in her baseline respiratory rate and work of breathing. She was then transferred to our institution for long term ventilation management. The admission chest radiograph (Fig. 8) shows bilateral bronchial wall thickening with persistent hyperlucency and inflation of the upper lobes.
During her inpatient stay, she was difficult to wean from ventilation, developing recurrent episodes of wheezing, and bronchoconstriction which were responsive to Ipratropium bromide and Salbutamol. Genetic testing was sought based on re-review of the external CT imaging. This was negative for cystic fibrosis and myotonin-protein kinase expansion but confirmed a novel variant missense mutation within the filamin A gene. Given the uncertainty regarding pathogenicity, the patient's immediate family members were all reviewed and tested for FLNA gene mutation. The patient's mother and younger sister were asymptomatic but found to have the identical missense mutation, and the patient's father did not. After prolonged discussion and genetic consultation, given the absence of other explainable lung disease, the consensus hypothesis was that the lung disease may have been manifested by an invoked unfavourable X inactivation in the patient.
Over the next years, the patient slowly improved with bronchodilator nebulization and satisfactory gas exchange on lower CPAP, tolerating periods on the Swedish nose during the day. She is now FIGURE 8 A supine chest radiograph of case 3 performed at 10 months of age demonstrates persistent upper lobe hyperinflation, flattening of both hemidiaphragms, and perihilar airspace changes. The patient has a tracheostomy in situ at this stage and is fed via a nasogastric tube (Fig. 9) . The subsequent chest CT demonstrated dilatation of the central pulmonary artery with bilateral extensive chronic lung disease with nodular change and bronchial wall thickening. In addition, hyperinflation of the upper lobes bilaterally were seen (Fig. 10) .
The patient was admitted to our institution for a hybrid procedure involving both cardiac catheterization and cardiac MRI. These studies revealed a PDA, confirmed bidirectional flow through the ASD and significant pulmonary arterial hypertension. The systemic and pulmonary venous connections were normal.
A respiratory consultation was sought and the pulmonary hypertension was presumed to be secondary to the diffuse lung disease. The patient was started on Bosentan in addition to her regular dose of Sildenafil. Investigations for aspiration, gastro-oesophageal reflux, immunodeficiency, and cystic fibrosis were all negative.
In view of the severe early onset cystic lung disease, she was screened for a Filamin A gene mutation, which was confirmed. She is currently 6 years old, and continues on supplementary oxygen support of 1 L at home and pulmonary vasodilators. Compared to the limited number of previously published cases (summarized in Table 2 ), our case series show similar features with our patients having an early age of onset of respiratory symptoms, presence of cardiac co-morbidities, pulmonary arterial hypertension (seen on echocardiography) and in one patient, the confirmatory diagnosis of periventricular nodular heterotopia on brain MRI. On chest imaging, all our patients demonstrated features both on radiography and CT of predominantly upper lobe hyperinflation and segmental basal atelectasis. This echoes previous cases where imaging appearances have been described as those featuring a combination of bronchopulmonary dysplasia, bronchomalacia, and congenital lobar emphysema.
11
With regards to the cardiac co-morbidities, two of our patients were found to have a patent ductus arteriosis, which was also seen in five previously reported FLNA associated lung disease cases 6, 10 and was the second commonest associated cardiac abnormality within 17.6%
(six patients) of patients with FLNA associated PVNH (second only to aortic valvular insufficiency). 13 This illustrates the importance of Interestingly, only two patients in this cohort had any respiratory symptoms described (these are not detailed further, apart from being described as "obstructive lung disease"). While we acknowledge a strong association between FLNA mutation and PVNH exists, given the young age of our patients, lack of neurological symptoms and increased risk from general anesthesia in order to perform the MRI studies (due to their lung disease), this was not felt to be clinically The pathogenesis of lung disease associated with FLNA mutations is unclear but a variety of hypotheses have been proposed. One explanation may be due to abnormal binding properties between Filamin A and beta integrin cell adhesion receptors, crucial in airway development. 15 The association between FLNA mutation with connective tissue disorders 16 may also suggest interplay with other gene abnormalities within the same functional pathway. These explanations have also been proposed to account for the associated cardiac anomalies in many observed cases of FLNA associated lung disease.
An alternative mechanism may be from atypical interactions of Filamin A with the cystic fibrosis transmembrane regulator (CFTR) thereby destabilizing chloride channel function in the airways. 17 This is however felt to be a less likely cause for the pulmonary features as florid bronchiectasis and impaired mucociliary fluid clearance has only been described in one patient so far with FLNA mutation. 11 Furthermore poor immunological function with a super-added infective etiology has been suggested due to the role played by Filamin A in T cell activation and interleukin production, 18 however, patients with the FLNA mutation have not shown susceptibility to any specific organisms despite many of the patients in our case series regularly presenting to hospital in childhood with recurrent pulmonary infections.
CONCLUSION
We present the clinical radiological, cardiac, and histological features of FLNA gene mutation ChILd. This diagnosis should be considered for atypical diffuse lung disease with the hallmark feature of marked hyperinflation, 19 predominantly in the upper lobe distribution with accompanying pulmonary arterial hypertension in the majority of cases. There may be a potential association with periventricular nodular heterotopia (PNH). 13 While the treatment options may be predominantly supportive, our case series has shown that some clinical improvements may be achieved and that the prognosis is variable.
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